MRT5005 Gets FDA Rare Pediatric Disease Status as Adult Trial Faces Delay Due to COVID-19
Translate Bio‘s therapy MRT5005 has been given a rare pediatric disease designation by the U.S. Food and Drug Administration (FDA) for the treatment of cystic fibrosis in children, while its ongoing clinical trial investigating the therapy in adult patients faces delays due to the COVID-19…